Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
12,086.70114.9
Stock Analysis, IPO, Mutual Funds, Bonds & More

Buy RNAM, target Rs 300: CLSA

Buy Reliance Nippon Life Asset Management at a price target of Rs 300.

ETMarkets.com|
Updated: Sep 30, 2019, 04.09 PM IST
0Comments
Getty Images
GettyImages-800473410
Reliance Nippon Life Asset Management Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 16246.53 Crore) operating in Financial Services sector.
CLSA has a buy call on Reliance Nippon Life Asset Management Ltd. with a target price of Rs 300. The current market price of Reliance Nippon Life Asset Management is Rs 259.80. Time period given by analyst is Long Term when Reliance Nippon Life Asset Management price can reach defined target.

Reliance Nippon Life Asset Management Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 16246.53 Crore) operating in Financial Services sector.

Reliance Nippon Life Asset Management Ltd. key Products/Revenue Segments include Investment Management & Advisory Fees which contributed Rs 1376.29 Crore to Sales Value (97.24 % of Total Sales) and Income From Portfolio Management Services which contributed Rs 38.97 Crore to Sales Value (2.75 % of Total Sales)for the year ending 31-Mar-2019.

For the quarter ended 30-06-2019, the company has reported a Consolidated sales of Rs 325.11 Crore, down -5.28 % from last quarter Sales of Rs 343.22 Crore and down -17.48 % from last year same quarter Sales of Rs 394.00 Crore Company has reported net profit after tax of Rs 125.60 Crore in latest quarter. The company’s top management includes GeneralVed Prakash Malik, Mr.Akira Shibata, Mr.Mahadevan Veeramony, Mr.Minoru Kimura, Mr.Sundeep Sikka, Ms.Ameeta Chatterjee. Company has S R Batliboi & Co. LLP as its auditoRs As on 30-06-2019, the company has a total of 612,000,000 shares outstanding.

Also Read

CLSA’s India division too witnessing an exodus

Glenmark soars over 21% on CLSA’s upgrade

Glenmark Pharma jumps 21% on CLSA upgrade

CLSA initiates coverage on Abbott India with buy rating

CLSA upgrades BHEL stock on divestment expectations

Comments
Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
Disclaimer: This recommendation is analyst's own and does not represent those of economictimes.com & ETMarkets.com. Please consult your financial advisor before taking any position in the stock/s mentioned.

Other useful Links


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service